tcf/β-catenin

BML-284 (Wnt agonist 1) is a potent, selective and , cell-permeable Wnt signaling activator.

ICG001 is a β-catenin TCF-mediated transcription inhibitor that selectively blocks β-catenin CBP interaction without interfering with β-catenin p300 interaction. It specifically binds to CREB protein with an IC50 of 3 μM.

CCT 031374 hydrobromide is a TCF β-catenin inhibitor with antitumor activities.

WAY262611 is a Wnt β-catenin agonist and an inhibitor of Dkk1. It increases bone formation rate with EC50 of 0.63 μM in TCF-luciferase assay.

ICG001 antagonizes Wnt β-catenin TCF-mediated transcription and specifically binds to element-binding protein (CREB)-binding protein (CBP) with IC50 of 3 μM, but is not the related transcriptional coactivator p300.

CWP232228, a potent and selective Wnt β-catenin signaling inhibitor, antagonizes the binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 inhibits the formation and metastasis of tumors by inhibiting the growth of breast cancer and live

FzM1.8 is an allosteric FZD4 agonist with a pEC50 of 6.4. FzM1.8 binds to FZD4, promotes TCF LEF transcriptional activity in the absence of any WNT ligand, and activates the WNT β-catenin pathway.

CCT070535 inhibits TCF-dependent transcription at the TCF level, displaying GI50 values of 17.6 μM in HT29 (APC mutation), 11.1 μM in HCT116 (oncogenic β-catenin), 11.8 μM in SW480 (APC mutation), and 13.4 μM in SNU475 (Axin mutation) cells.

BML-286 is a WNT pathway modulator with potential anticancer activity, inducing β-catenin- and TCF-dependent transcriptional activity, and can be used in the study of degenerative diseases, intestinal, breast, bladder, gastric, melanoma, leukemia, hepatocellular carcinoma and nephroblastoma.

β-Catenin-IN-37 is a selective inhibitor of the protein-protein interaction between β-Catenin and T-cell factor (Tcf), known as β-catenin/Tcf PPI. It effectively inhibits canonical Wnt signaling and impedes the growth of colorectal cancer cells SW480 and HCT116, with IC50 values of 20 μM and 31 μM, respectively.

CDK8-IN-11 is a selective and potent CDK8 inhibitor that shows antiproliferative activity in colon cancer cell lines, inhibiting WNT β-catenin activation and TCF family transcriptional activity, inducing G1-phase arrest in HCT-116 cells, useful for colon cancer research.

UU-T01 is a selective inhibitor of the β-Catenin T-cell factor 4 (β-catenin Tcf) protein-protein interaction (PPI), exhibiting a Ki value of 3.14 µM, and directly binds to β-catenin with a KD value of 0.531 µM.

Streptonigrin is an aminoquinone antitumor and antibacterial antibiotic produced by Streptomyces flocculus. Streptonigrin inhibits β-Catenin Tcf signaling and shows cytotoxicity in β-catenin-activated cells. Streptonigrin induces delayed chromosomal instability involving interstitial telomeric sequences in Chinese hamster ovary cells. Note: Streptonigrin from natural resource is (-)-rotation, has CAS#3930-19-6 and is a R-isomer.

Murayaquinone is a hepatitis C virus proteinase inhibitor and small molecule antagonist of the oncogenic Tcf β-catenin protein complex.

β-Catenin-IN-7 (Compound 9) is an inhibitor of β-catenin that disrupts its interaction with Tcf-4, consequently impeding Wnt-dependent gene expression, and exhibits anticancer activity [1].

Pterostilbene-isothiocyanate (PTER-ITC) demonstrates strong anticancer properties in vitro, particularly disrupting the interaction between β-catenin and TCF-4 in human osteosarcoma cells [1].

BML-284 hydrochloride (Wnt agonist 1 HCL) is a potent, selective Wnt canonical signaling activator and tubulin polymerization inhibitor.

β-catenin-IN-2, a potent inhibitor of β-catenin, is suitable for use in colorectal cancer research.

fStAx-35R TFA is a hydrophobic carbon chain-stabilized peptide that inhibits the Wnt β-catenin signaling pathway by disrupting the β-catenin-TCF interaction. This compound is utilized in cancer research.

I-66 is a potent β-catenin inhibitor with an IC50 of less than 50 nM. It disrupts the interaction between β-catenin and T cell factor (TCF) transcription factors and exhibits anticancer properties.